HC Wainwright Decreases Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright cut their Q1 2025 EPS estimates for Gossamer Bio in a report released on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.16) for the quarter, down from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Down 4.2 %

GOSS stock opened at $1.36 on Thursday. The business’s 50-day moving average price is $1.15 and its 200-day moving average price is $0.98. The stock has a market cap of $308.18 million, a P/E ratio of -4.25 and a beta of 1.86. Gossamer Bio has a twelve month low of $0.50 and a twelve month high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15). The company had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million.

Institutional Trading of Gossamer Bio

Hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its position in shares of Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after purchasing an additional 13,902 shares in the last quarter. Graham Capital Management L.P. purchased a new position in Gossamer Bio during the 4th quarter valued at approximately $32,000. Geode Capital Management LLC grew its holdings in Gossamer Bio by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company’s stock valued at $2,037,000 after buying an additional 38,084 shares in the last quarter. Bank of America Corp DE increased its stake in Gossamer Bio by 107.2% in the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after acquiring an additional 43,866 shares during the last quarter. Finally, Fullcircle Wealth LLC purchased a new stake in shares of Gossamer Bio during the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.